Sixty patients who participated in the Genome-based Therapeutic Drugs for Depression study with a diagnosis of moderate or severe episodes of depression according to the International Classification of Diseases , 10th Revision , and the Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition , criteria were involved .